DeepMed Research

Atacicept

Generic Name: Atacicept

Drug Type: Biotech

CAS Number: 845264-92-8

Unique Ingredient Identifier: K3D9A0ICQ3

Background: Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI.

Indication: Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).

Clinical Trials

Atacicept in Multiple Glomerular Diseases

Phase 2

Not yet recruiting

Conditions: pMN
IgAN
Nephrotic Syndrome
MCD
FSGS

Interventions: Drug: Atacicept

First Posted Date: 2025-05-21

Last Posted Date: 2025-05-21

Lead Sponsor: Vera Therapeutics, Inc.

Target Recruit Count: 200

Registration Number: NCT06983028

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Phase 2

Conditions: IgA Nephropathy (IgAN)
Renal and Urinary Disorders
Berger Disease

Interventions: Drug: Atacicept 150 mg

First Posted Date: 2024-11-05

Last Posted Date: 2025-04-08

Lead Sponsor: Vera Therapeutics, Inc.

Target Recruit Count: 476

Registration Number: NCT06674577

Locations: 🇺🇸
Vera Therapeutics, Brisbane, California, United States

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

Phase 3

Suspended

Conditions: Lupus Nephritis (LN)

Interventions: Drug: Placebo
Drug: Atacicept

First Posted Date: 2022-11-08

Last Posted Date: 2023-07-05

Lead Sponsor: Vera Therapeutics, Inc.

Target Recruit Count: 360

Registration Number: NCT05609812

Locations: 🇺🇸
Vera Site # 0131, Torrance, California, United States
🇺🇸
Vera Site # 0125, Dallas, Texas, United States
🇺🇸
Vera Site # 0128, Miami, Florida, United States

and more 30 locations

Atacicept in Subjects With IgA Nephropathy

Phase 3

Active, not recruiting

Conditions: IgA Nephropathy
Berger Disease

Interventions: Other: Placebo to match Atacicept
Biological: Atacicept

First Posted Date: 2021-01-20

Last Posted Date: 2025-05-04

Lead Sponsor: Vera Therapeutics, Inc.

Target Recruit Count: 376

Registration Number: NCT04716231

Locations: 🇺🇸
ORIGIN 3 Global Site Contact Information, Brisbane, California, United States

Efficacy and Safety of Atacicept in IgA Nephropathy

Phase 2

Terminated

Conditions: IgA Nephropathy

Interventions: Drug: Atacicept 75 mg
Drug: Placebo
Drug: Atacicept 25 mg

First Posted Date: 2016-06-21

Last Posted Date: 2021-02-25

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 16

Registration Number: NCT02808429

Locations: 🇺🇸
Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent, Columbus, Ohio, United States
🇺🇸
Southeastern Clinical Research Institute, LLC, Augusta, Georgia, United States
🇺🇸
California Institute of Renal Research - Chula Vista Location, Chula Vista, California, United States

and more 15 locations

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

Phase 2

Terminated

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Atacicept 150 mg
Drug: Atacicept 75 mg

First Posted Date: 2014-02-25

Last Posted Date: 2019-03-21

Lead Sponsor: EMD Serono

Target Recruit Count: 253

Registration Number: NCT02070978

Locations: 🇲🇽
Clinica de Enfermedades Cronicas y de Procedimientos Especiales, S.C., Morelia, Michoacán, Mexico
🇵🇭
Mary Mediatrix Medical Center, Batangas, Philippines
🇲🇽
Icle S.C., Guadalajara, Jalisco, Mexico

and more 81 locations

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Atacicept 75 milligram (mg)
Drug: Placebo
Drug: Atacicept 150 mg

First Posted Date: 2013-10-30

Last Posted Date: 2018-01-02

Lead Sponsor: EMD Serono

Target Recruit Count: 306

Registration Number: NCT01972568

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇦🇷
Atencion Integral en Reumatologia (AIR), Ciudad Autonoma Buenos Aires, Argentina
🇦🇷
Organizacion Medica de Investigacion (OMI), Ciudad Autonoma Buenos Aires, Argentina

and more 134 locations

Atacicept Demonstrating Dose RESponSe

Phase 2

Withdrawn

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Atacicept
Drug: Placebo

First Posted Date: 2011-09-26

Last Posted Date: 2013-08-21

Lead Sponsor: EMD Serono

Registration Number: NCT01440231

Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

Phase 1

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Atacicept

First Posted Date: 2011-06-09

Last Posted Date: 2013-10-22

Lead Sponsor: EMD Serono

Target Recruit Count: 1

Registration Number: NCT01369628

Locations: 🇺🇸
EMD Serono Inc., One Technology Place, Rockland, Massachusetts, United States

Atacicept in Multiple Sclerosis Extension Study, Phase II

Phase 2

Terminated

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Atacicept 150 mg
Drug: Atacicept 25 mg
Drug: Atacicept 75 mg

First Posted Date: 2009-03-02

Last Posted Date: 2017-03-20

Lead Sponsor: EMD Serono

Target Recruit Count: 74

Registration Number: NCT00853762

Locations: 🇬🇧
Research Site, Stoke on Trent, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy